A Phase 1 interventional study of Obicetrapib and Obicetrapib + Drospirenone / Ethinyl Estradiol (COC) in Healthy Volunteers, sponsored by NewAmsterdam Pharma. Completed at 1 site in United States. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by NewAmsterdam Pharma · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study to evaluate the impact of Obicetrapib on the PK levels of Drospirenone and Ethinyl Estradiol (COC) in 30 adult female, healthy volunteers.
This is an interventional, drug-drug interaction study to evaluate the effect of daily doses of Obicetrapib tablets on the pharmacokinetics of a combined oral contraceptive (COC), Drospirenone and Ethinyl Estradiol.
NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Obicetrapib 10 mg tablets and Drospirenone (3mg)/Ethinyl Estradiol (0.02mg) tablet
Drug: Obicetrapib · Drug: Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)
Obicetrapib 10 mg tablets (daily)
Drug: Obicetrapib
Drospirenone (3mg)/Ethinyl Estradiol tablets (0.02mg) tablet
Drug: Drospirenone / Ethinyl Estradiol (COC)
oral administration
Also known as: 10 mg tablet
Drug pages: TA-8995 · Drospirenone · Ethinyl Estradiol
oral administration
Also known as: tablets
Drug pages: Drospirenone · Ethinyl Estradiol
oral administration
Also known as: tablets
Maximum observed plasma concentration (Cmax) of COC
Plasma Cmax concentration of COC with and without Obicetrapib
Time frame: Upon completion of Treatment C (Day -6) and Treatments B+C (Day 12)
Area under the plasma concentration-time (AUC0-τ) curve for COC with and without coadministration with Obicetrapib
Plasma AUC0-τ for COC with and without coadministration of Obicetrapib
Time frame: Upon completion of Treatment C (Day -6) and Treatments B+C (Day 12)
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2024 to primary completion in Apr 2024, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: TA-8995 · Drospirenone · Ethinyl Estradiol
NewAmsterdam Pharma